Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue
NCT ID: NCT05778110
Last Updated: 2023-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2023-04-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Which RNA, protein and metabolites are differently expressed in lesion tissues?
* What molecular mechanism is participated in TBI or ICH? Participants will be treated by emergency operation, and their lesion tissues will be collected during the operation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiomic Analysis of Body Fluid in Acute Traumatic Brain Injury
NCT05778123
Multiomic Analysis of Serum in Acute Period of Traumatic Brain Injury
NCT05867992
Rapid Diagnosis and Prognosis Recognition of Imaging and Biomarkers in Mild to Moderate Traumatic Brain Injury
NCT05108909
Clinical and Molecular Biological Data Collection and Analysis in Patients With TBI
NCT05533060
Comparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI)
NCT06429774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TBI
Patients with traumatic brain injury.
Type of disease
Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
ICH
Patients with hypertensive intracranial hemorrhage.
Type of disease
Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Type of disease
Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Within 12 hours after brain injury
3. GCS ≥3 and ≤8
4. Closed brain injury with frontotemporal contusion or basal ganglia intracranial hemorrhage
5. Need emergency intracranial hematoma evacuating operation
6. Patient's agents are informed and consent the research
Exclusion Criteria
2. Death within 24 hours
3. Immunosuppression state
4. Severe organ dysfunction
5. Complicated infective disease
6. Pregnant
16 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junfeng Feng
Director of Brain Injury Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Junfeng Feng
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LY2023-017-B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.